Lyra Therapeutics Inc is a pioneering biotech firm dedicated to advancing the treatment of ear, nose, and throat diseases. With its innovative XTreo technology platform, Lyra aims to revolutionize patient care by delivering medications directly to the affected areas for extended periods with just a single application. The company is actively developing LYR-210, a promising anti-inflammatory treatment for chronic rhinosinusitis, currently in Phase II trials. Originally known as 480 Biomedical, Inc., Lyra rebranded in 2018 and is based in Watertown, Massachusetts.